120 related articles for article (PubMed ID: 12188955)
1. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.
Deniz ML; Kiliç T; Almaata I; Kurtkaya O; Sav A; Pamir MN
Neurosurgery; 2002 Sep; 51(3):753-60; discussion 760. PubMed ID: 12188955
[TBL] [Abstract][Full Text] [Related]
2. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
3. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Salmas M; Malamou-Mitsi V
BJU Int; 2005 Mar; 95(4):655-9. PubMed ID: 15705098
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus.
Lord RV; Park JM; Wickramasinghe K; DeMeester SR; Oberg S; Salonga D; Singer J; Peters JH; Danenberg KD; Demeester TR; Danenberg PV
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):246-53. PubMed ID: 12579092
[TBL] [Abstract][Full Text] [Related]
5. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization.
Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H
Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296
[TBL] [Abstract][Full Text] [Related]
6. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A; Kuwahara M; Yoshinaga Y; Shirakusa T
Eur J Cardiothorac Surg; 2004 Mar; 25(3):443-8. PubMed ID: 15019676
[TBL] [Abstract][Full Text] [Related]
7. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
8. Expression of angiogenic factors in craniopharyngiomas: implications for tumor recurrence.
Sun HI; Akgun E; Bicer A; Ozkan A; Bozkurt SU; Kurtkaya O; Koc DY; Pamir MN; Kilic T
Neurosurgery; 2010 Apr; 66(4):744-50; discussion 750. PubMed ID: 20190664
[TBL] [Abstract][Full Text] [Related]
9. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas.
Tzortzidis F; Elahi F; Wright D; Natarajan SK; Sekhar LN
Neurosurgery; 2006 Aug; 59(2):230-7; discussion 230-7. PubMed ID: 16883163
[TBL] [Abstract][Full Text] [Related]
10. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
11. [Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) expression in superficial transitional cell bladder carcinoma].
Guo ZH; Mei H; Huang J; Li SY
Ai Zheng; 2003 Mar; 22(3):307-9. PubMed ID: 12654193
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of tissue endostatin in human malignant gliomas.
Morimoto T; Aoyagi M; Tamaki M; Yoshino Y; Hori H; Duan L; Yano T; Shibata M; Ohno K; Hirakawa K; Yamaguchi N
Clin Cancer Res; 2002 Sep; 8(9):2933-8. PubMed ID: 12231538
[TBL] [Abstract][Full Text] [Related]
13. Expression of structural proteins and angiogenic factors in normal arterial and unruptured and ruptured aneurysm walls.
Kilic T; Sohrabifar M; Kurtkaya O; Yildirim O; Elmaci I; Günel M; Pamir MN
Neurosurgery; 2005 Nov; 57(5):997-1007; discussion 997-1007. PubMed ID: 16284569
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Ann Diagn Pathol; 2003 Feb; 7(1):1-8. PubMed ID: 12616467
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.
Alabi AA; Suppiah A; Madden LA; Monson JR; Greenman J
Dis Colon Rectum; 2009 May; 52(5):993-9. PubMed ID: 19502868
[TBL] [Abstract][Full Text] [Related]
18. [A long term follow-up study of the skull base chordomas].
Wu Z; Zhang JT; Zhang LW; Jia GJ; Wang L
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1118-20. PubMed ID: 18005615
[TBL] [Abstract][Full Text] [Related]
19. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
20. Multimodality management of 26 skull-base chordomas with 4-year mean follow-up: experience at a single institution.
Pamir MN; Kiliç T; Türe U; Ozek MM
Acta Neurochir (Wien); 2004 Apr; 146(4):343-54; discusion 354. PubMed ID: 15057528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
